LifeMD earnings release, May 6, 2026

LifeMD, Inc. (LFMD) · Form 8-K, Item 2.02 · Filed · SEC filing

Exhibit

99.1

LifeMD

Reports First Quarter 2026 Results

Conference call begins at 4:30 p.m. Eastern time today

NEW

YORK, May 6, 2026 — LifeMD, Inc.

(Nasdaq: LFMD), a leading platform for virtual primary care services, today reported financial results for the first quarter ended March 31, 2026.

Management

Commentary

“Q1 was a strong start to 2026. We added more than 42,000 net telehealth subscribers, the largest quarterly net addition in our history.

We ended the quarter with over 365,000 subscribers. In weight management, sign-ups increased approximately 120% sequentially from Q4, and we exited the quarter with strong momentum across all of our key growth areas,” said Justin Schreiber, Chairman and CEO of

LifeMD.

“LifeMD is no longer just a telehealth company focused on a handful of conditions. We are building what we believe can become one of the most important virtual healthcare platforms in the country — a trusted destination where patients can access care, medications, labs, insurance-supported services, and ongoing clinical support through one connected experience.

“Our platform is uniquely positioned to support both direct-to-consumer self-pay and insurance-covered programs, and we are seeing continued traction with strong unit economics across our insurance-sponsored offerings. As previously guided, we are on track to expand coverage to approximately 230 million lives this month and believe our benefits infrastructure will be a key driver of long-term growth.

“At the same time, our women’s health business delivered exceptional performance in the quarter, with strong retention and improved customer acquisition costs supporting scalable, high-quality growth. Looking ahead, we are energized by the momentum across the business, with multiple strategic partnerships and new product launches in men’s and women’s health expected in the coming months, positioning us to drive continued top-line growth and profitability throughout the year,” concluded Mr. Schreiber.

“The first quarter played out largely as we expected: strong subscriber momentum, following a planned step-up in patient acquisition spend, and the early benefits of platform efficiency beginning to show in our gross margin,” said Atul Kavthekar, Chief Financial Officer of LifeMD. “Revenue for the first quarter was $50.2 million, exceeding our guidance range of $48 million to $49 million, with nearly all revenue derived from recurring subscriptions. The number of active subscribers increased approximately 26% year-over-year to over

365,000 at quarter end, with over 42,000 net adds in Q1, the largest quarterly net addition in our history. We exited the quarter with

$34.5 million in cash, no debt, and a $30 million undrawn revolving credit facility that we put in place at the start of the year. Our balance sheet remains a strategic asset, providing ample flexibility to fund our expanding growth initiatives.”

First

Quarter 2026 Financial Highlights

All comparisons are with the first quarter of 2025 on a continuing operations basis (excluding WorkSimpli, which was divested on November 4, 2025, and is reported as discontinued operations for all periods presented). Non-GAAP financial measures referenced below are defined and reconciled to the most directly comparable GAAP measures at the end of this press release.

First

Quarter Key Performance Metrics

Financial

Guidance

For the second quarter of 2026, the Company expects:

For the full year 2026, the Company affirms its previously issued guidance:

Conference

Call

LifeMD’s management will host a conference call today at 4:30 p.m. Eastern time to discuss the Company’s financial results and outlook, and answer questions. Details for the call are as follows:

A live and archived webcast will be available in the Investors section of the Company’s website at ir.lifemd.com.

About

LifeMD, Inc.

LifeMD® is a leading provider of virtual primary care. LifeMD offers telemedicine, access to laboratory and pharmacy services, and specialized treatment across more than 200 conditions, including primary care, men’s and women’s health, weight management, and hormone therapy. The Company leverages a vertically integrated, proprietary digital care platform, a 50-state affiliated medical group, a state-of-the-art affiliated pharmacy, and a U.S.-based patient care center to increase access to high-quality and affordable care. For more information, please visit

LifeMD.com.

Cautionary

Note Regarding Forward Looking Statements

Financial statements

Income Statement

Three Months Ended March 31, — (Unaudited)

Three Months Ended March 31, – 2026Three Months Ended March 31, – 2025
Telehealth revenue, net50,162,95650,887,899
Cost of telehealth revenue5,925,4998,136,462
Gross profit44,237,45742,751,437
ExpensesSelling and marketing expenses29,874,86022,272,924
ExpensesGeneral and administrative expenses15,176,35514,340,151
ExpensesOther operating expenses3,179,9462,389,536
ExpensesCustomer service expenses3,139,3053,071,494
ExpensesDevelopment costs1,796,0631,859,049
ExpensesTotal expenses53,166,52943,933,154
ExpensesOperating loss from continuing operations-8,929,072-1,181,717
ExpensesInterest income (expense), net56,476-463,638
ExpensesLoss from continuing operations before income taxes-8,872,596-1,645,355
ExpensesNet loss from continuing operations-8,872,596-1,645,355
ExpensesNet income from discontinued operations1,993,422
ExpensesNet (loss) income-8,872,596348,067
ExpensesNet income attributable to noncontrolling interests of discontinued operations531,845
ExpensesNet loss attributable to LifeMD, Inc.-8,872,596-183,778
ExpensesPreferred stock dividends-776,563-776,563
ExpensesNet loss attributable to LifeMD, Inc. common stockholders-9,649,159-960,341
Basic (loss) earnings per share attributable to LifeMD, Inc. common stockholdersContinuing operations-0.2-0.06
Basic (loss) earnings per share attributable to LifeMD, Inc. common stockholdersDiscontinued operations0.03
Basic (loss) earnings per share attributable to LifeMD, Inc. common stockholdersBasic loss per share-0.2-0.02
Diluted (loss) earnings per share attributable to LifeMD, Inc. common stockholdersContinuing operations-0.2-0.06
Diluted (loss) earnings per share attributable to LifeMD, Inc. common stockholdersDiscontinued operations0.03
Diluted (loss) earnings per share attributable to LifeMD, Inc. common stockholdersDiluted loss per share-0.2-0.02
Weighted average number of common shares outstanding:Basic47,336,06043,135,778
Weighted average number of common shares outstanding:Diluted47,336,06043,135,778

Balance Sheet

March 31, 2026 — (Unaudited)

March 31, 2026December 31, 2025
Current AssetsCash34,478,13736,786,318
Current AssetsAccounts receivable9,855,1179,305,277
Current AssetsProduct deposit331,525320,217
Current AssetsInventory, net3,177,1362,773,576
Current AssetsOther current assets3,855,1312,646,077
Current AssetsTotal Current Assets51,697,04651,831,465
Non-current AssetsEquipment, net2,260,4372,444,717
Non-current AssetsRight of use assets, net5,055,0905,267,857
Non-current AssetsCapitalized software, net10,881,67810,604,946
Non-current AssetsIntangible assets, net230,417262,334
Non-current AssetsTotal Non-current Assets18,427,62218,579,854
Non-current AssetsTotal Assets70,124,66870,411,319
Current LiabilitiesAccounts payable21,653,12214,149,154
Current LiabilitiesAccrued expenses15,244,96315,974,016
Current LiabilitiesCurrent operating lease liabilities670,825642,422
Current LiabilitiesDeferred revenue12,016,84010,807,773
Current LiabilitiesTotal Current Liabilities49,585,75041,573,365
Long-term LiabilitiesNon-current operating lease liabilities5,502,0725,681,374
Long-term LiabilitiesTotal Liabilities55,087,82247,254,739
Stockholders’ EquitySeries A Preferred Stock, $0.0001 par value; 1,610,000 shares authorized, 1,400,000 shares issued and outstanding as of March 31, 2026 and December 31, 2025140140
Stockholders’ EquityCommon Stock, $0.01 par value; 100,000,000 shares authorized, 47,632,707 and 46,760,016 shares issued, 47,529,667 and 46,656,976 outstanding as of March 31, 2026 and December 31, 2025, respectively476,327467,600
Stockholders’ EquityAdditional paid-in capital252,976,314251,455,616
Stockholders’ EquityAccumulated deficit-238,252,234-228,603,075
Stockholders’ EquityTreasury stock, 103,040 shares, at cost, as of March 31, 2026 and December 31, 2025-163,701-163,701
Stockholders’ EquityTotal LifeMD, Inc. Stockholders’ Equity15,036,84623,156,580
Stockholders’ EquityTotal Liabilities and Stockholders’ Equity70,124,66870,411,319

Cash Flow

Three Months Ended March 31, — (Unaudited)

Three Months Ended March 31, – 2026Three Months Ended March 31, – 2025
CASH FLOWS FROM OPERATING ACTIVITIESNet (loss) income-8,872,596348,067
CASH FLOWS FROM OPERATING ACTIVITIESLess: Net income from discontinued operations1,993,422
CASH FLOWS FROM OPERATING ACTIVITIESNet loss from continuing operations-8,872,596-1,645,355
Adjustments to reconcile net loss from continuing operations to net cash provided by operating activities:Amortization of debt discount100,444
Adjustments to reconcile net loss from continuing operations to net cash provided by operating activities:Amortization of capitalized software1,674,8521,529,380
Adjustments to reconcile net loss from continuing operations to net cash provided by operating activities:Amortization of intangibles31,9176,667
Adjustments to reconcile net loss from continuing operations to net cash provided by operating activities:Depreciation of fixed assets289,458155,361
Adjustments to reconcile net loss from continuing operations to net cash provided by operating activities:Noncash operating lease expense212,767269,888
Adjustments to reconcile net loss from continuing operations to net cash provided by operating activities:Stock compensation expense1,448,9052,548,528
Changes in Assets and LiabilitiesAccounts receivable-549,840-459,948
Full release

This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended; Section

21E of the Securities Exchange Act of 1934, as amended; and the safe harbor provision of the U.S. Private Securities Litigation Reform

Act of 1995. Forward-looking statements contained in this news release may be identified by the use of words such as: “believe,”

“expect,” “anticipate,” “project,” “should,” “plan,” “will,”

“may,” “intend,” “estimate,” predict,” “continue,” and “potential,” or, in each case, their negative or other variations or comparable terminology referencing future periods. Examples of forward-looking statements include, but are not limited to, statements regarding our financial outlook and guidance, short and long-term business performance and operations, future revenues and earnings, regulatory developments, legal events or outcomes, ability to comply with complex and evolving regulations, market conditions and trends, new or expanded products and offerings, growth strategies, underlying assumptions, and the effects of any of the foregoing on our future results of operations or financial condition.

Forward-looking statements are not historical facts and are not assurances of future performance. Rather, these statements are based on our current expectations,... (truncated) regarding future plans and strategies, projections, anticipated and unanticipated events and trends, the economy, and other future conditions, including the impact of any of the aforementioned on our future business. As forward-looking statements relate to the future, they are subject to inherent risk, uncertainties, and changes in circumstances and assumptions that are difficult to predict, including some of which are out of our control. Consequently, our actual results, performance, and financial condition may differ materially from those indicated in the forward-looking statements. These risks and uncertainties include, but are not limited to, “Risk Factors” identified in our filings with the Securities and Exchange Commission, including, but not limited to, our most recently filed Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and any amendments thereto. Even if our actual results, performance, or financial condition are consistent with forward-looking statements contained in such filings, they may not be indicative of our actual results, performance, or financial condition in subsequent periods.

Any forward-looking statement made in the news release is based on information currently available to us as of the date on which this release is made. We undertake no obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, except as may be required under applicable law or regulation.

Investor

Contact ir@lifemd.com

Media

Contact press@lifemd.com

Tables to Follow

++++++

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · LifeMD earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.